Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide as Adjuvant Therapy for TACE in Advanced HCC
NCT00921531Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Jun 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in hepatocellular carcinoma (HCC), sponsored by Fudan University. Status: unknown.
02
Drugs
thalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00921531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921531.